Market Overview

Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate Complexity' by FDA

Cepheid (NASDAQ: CPHD) today announced the U.S. Food & Drug Administration (FDA) has categorized Cepheid's Xpert® CT/NG test as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments (CLIA). Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The test runs on Cepheid's GeneXpert® Systems and is the first and only molecular CT/NG test to be categorized as Moderately Complex. The Moderately Complex categorization will now allow the accuracy benefits of molecular diagnostics to be realized over a broader testing universe.

(Photo: http://photos.prnewswire.com/prnh/20130115/LA42508)

"In a recent study of 23 developed countries by the Institute of Medicine and the National Research Council, the U.S. was found to have the highest rates of Sexually Transmitted Diseases among youths1," said John Bishop, Cepheid's Chief Executive Officer. "Now accessible to more than 20,000 Moderately Complex U.S. labs and 7,000 High Complexity U.S. labs, Xpert CT/NG becomes an important new weapon in reducing STD rates as clinicians can test, consult with, and treat their patients on a more timely basis."

"The classification of Xpert CT/NG by

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (CPHD)

Around the Web, We're Loving...

Get Benzinga's Newsletters